Arhinia, or absence of the nose, is a rare malformation of unknown etiology that is often accompanied by ocular and reproductive defects. Sequencing of 40 people with arhinia revealed that 84% of probands harbor a missense mutation localized to a constrained region of SMCHD1 encompassing the ATPase domain. SMCHD1 mutations cause facioscapulohumeral muscular dystrophy type 2 (FSHD2) via a trans-acting loss-offunction epigenetic mechanism. We discovered shared mutations and comparable DNA hypomethylation patterning between these distinct disorders. CRISPR/Cas9-mediated alteration of smchd1 in zebrafish yielded arhinia-relevant phenotypes. Transcriptome and protein analyses in arhinia probands and controls showed no differences in SMCHD1 mRNA or protein abundance but revealed regulatory changes in genes and pathways associated with craniofacial patterning. Mutations in SMCHD1 thus contribute to distinct phenotypic spectra, from craniofacial malformation and reproductive disorders to muscular dystrophy, which we speculate to be consistent with oligogenic mechanisms resulting in pleiotropic outcomes.
Arhinia, or absence of the nose, is a rare malformation of unknown etiology that is often accompanied by ocular and reproductive defects. Sequencing of 40 people with arhinia revealed that 84% of probands harbor a missense mutation localized to a constrained region of SMCHD1 encompassing the ATPase domain. SMCHD1 mutations cause facioscapulohumeral muscular dystrophy type 2 (FSHD2) via a trans-acting loss-offunction epigenetic mechanism. We discovered shared mutations and comparable DNA hypomethylation patterning between these distinct disorders. CRISPR/Cas9-mediated alteration of smchd1 in zebrafish yielded arhinia-relevant phenotypes. Transcriptome and protein analyses in arhinia probands and controls showed no differences in SMCHD1 mRNA or protein abundance but revealed regulatory changes in genes and pathways associated with craniofacial patterning. Mutations in SMCHD1 thus contribute to distinct phenotypic spectra, from craniofacial malformation and reproductive disorders to muscular dystrophy, which we speculate to be consistent with oligogenic mechanisms resulting in pleiotropic outcomes.
Arhinia, or the complete absence of an external nose, is a rare congenital malformation reported in only 80 patients without holoprosencephaly in the past century (Supplementary Table 1 ). This severe malformation can be isolated or accompanied by other craniofacial defects, including anophthalmia, coloboma, cataracts, nasolacrimal duct atresia, choanal atresia and cleft palate (Fig. 1) . Seventeen patients with arhinia and ocular defects have been reported with coexistent hypogonadotropic hypogonadism, a triad called Bosma arhinia microphthalmia syndrome (BAM; MIM603457) 1 . The rarity of these malformations and the cross-disciplinary nature of coexistent features have limited efforts to systematically catalog associated phenotypes, though these comorbidities suggest that the genetic architecture underlying this condition has broad developmental implications.
Genetic studies of arhinia have been limited to targeted approaches related to cranial neural crest cells (NCC) or craniofacial placodal development. To date, no causal locus has been identified. Homozygous null mutations in Pax6 arrest nasal placodogenesis in mice 2 and (in PAX6) cause rudimentary or malformed noses in humans [3] [4] [5] , yet null mutations in PAX6 also cause aniridia and structural brain abnormalities that are not observed in individuals with arhinia [3] [4] [5] . We formed an international consortium to aggregate all available cases and determine the genetic etiology of arhinia. We sequenced 40 individuals with arhinia (38 independent families) and 55 family members without arhinia using a combination of SMCHD1 mutations associated with a rare muscular dystrophy can also cause isolated arhinia and Bosma arhinia microphthalmia syndrome whole-exome, whole-genome and targeted sequencing. These analyses revealed that rare missense variants in SMCHD1 represent the predominant genetic contributor to arhinia. Notably, SMCHD1 encodes a protein with established epigenetic repressive activities that has been implicated in FSHD2 (MIM158901), a rare, oligogenic form of muscular dystrophy. Methylation studies in arhinia subjects and complementation testing of arhinia-and FSHD2-associated variants in zebrafish (Danio rerio) revealed a common direction of allele effect in these disorders, a surprising observation considering their substantial differences in phenotype. Supporting these results, we observed the same mutations in BAM and FSHD2 probands, as well as at least one individual that met all diagnostic criteria and displayed symptoms for both disorders. Given the known oligogenic architecture of FSHD2, these results suggest that missense variants in an evolutionarily constrained region of SMCHD1 contribute to the diverse manifestations of arhinia, BAM and FSHD2, probably as a result of alteration to a critical function of the protein and/or interaction with other genomic loci.
RESULTS

Samples, phenotypes and epidemiology of arhinia
Our international consortium established a cohort of 40 subjects (38 probands and 2 affected siblings) that encompassed 24% of all 80 previously reported individuals and 21 new cases, facilitating a comprehensive phenotypic picture of arhinia and its associated comorbidities ( Supplementary Tables 1 and 2 ). Six subjects were also included in an independent analysis by Gordon et al. 6 .
All subjects had complete arhinia, accompanied in most cases by other craniofacial abnormalities, including high-arched or cleft palate, absent paranasal sinuses, hypoplastic maxilla, nasolacrimal duct stenosis or atresia and choanal atresia (Fig. 1) , and 41% had dysmorphic pinnae or low-set ears. Ocular phenotypes included anophthalmia or microphthalmia (77%), uveal coloboma (79%) and cataract (53%), and six subjects had normal eye anatomy and vision. Of the 31 assessable subjects (22 male; 9 female), 97% demonstrated hypogonadotropic hypogonadism (HH), and the seven subjects for whom brain MRI data were available had no olfactory structures. Fate mapping would support arhinia as a primary malformation, with HH representing a developmental sequence 7 . Ocular defects, which are not an obvious part of a developmental sequence with arhinia, were observed in 26 of 31 individuals, indicating that 84% of subjects met BAM diagnostic criteria.
Gene discovery
We sequenced all 40 arhinia subjects as well as 55 family members representing six multiplex and 32 simplex families. We performed whole-exome sequencing (WES) on 27 arhinia subjects and targeted sequencing in 16 subjects, and we applied both methods to 4 probands (Online Methods and Supplementary Fig. 1 ). Whole-genome sequencing (WGS) was concurrently performed in four members of a multiplex family (family O) that included a proband and affected sister with BAM, a half-aunt with arhinia and relatives with subphenotypes including anosmia and subtle nasal and dental anomalies 8, 9 a b c d e f g h i j Figure 1 Phenotypic spectra associated with arhinia. (a-e) Five representative subjects demonstrate complete arhinia and variable ocular phenotypes: Subject V1 (age 2) with left-sided iris coloboma (a), subject AC1 (age 10) with left-sided microphthalmia and bilateral nasolacrimal duct stenosis (b), subject U1 (as a newborn) with normal eye anatomy and vision (c), subject O4 (age 16) with right-sided microphthalmia (d) and subject A1 (age 1) with bilateral colobomatous microphthalmia, cataracts and nasolacrimal duct atresia (e). (f-j) Craniofacial radiographic images from subject V1: surface rendering reconstruction from a MRI 3D T1 weighted sequence showing complete absence of the nose (arrow) (f), 3D volume rendering technique (VRT) reconstruction from spiral CT showing complete absence of nasal bones (arrow) (g), coronal reconstruction from CT showing absence of nasal septal structures (h; the maxilla articulates with the nasal process of the frontal bone (arrow)), coronal MRI T2 weighted sequence showing absence of the olfactory bulb and olfactory sulcus (arrow) (i) and midline MRI sagittal T1 weighted sequence (j) showing a high-arched palate (cleft not visible on this image) and decreased distance between the oral cavity and the anterior cranial fossa (black arrow). The rudimentary nasopharynx (j, asterisk) is blind and air filled. The pituitary gland (j, white arrow) appears normal.
A r t i c l e s (Supplementary Fig. 1 ). Collectively, these analyses identified rare missense variants in SMCHD1 in 84% of probands (32/38), none of which were present in the Exome Aggregation Consortium 10 (ExAC, n = 60,706). To test whether this represented an unexpected accumulation of rare missense variants, we compared the rare mutation burden among 22,445 genes in the initial 22 probands with WES to variants observed in ExAC (minor allele frequency (MAF) < 0.1%). Powered by the size of our aggregate cohort, we found only one gene that achieved genome-wide significance: SMCHD1 (P = 2.9 × 10 −17 , twosided Fisher's exact test; odds ratio (OR) of 34.4 (95% CI 18.8-57.9); Fig. 2 ). This result was significant irrespectively of ethnicity (Supplementary Table 3) . Notably, in an independent study, Gordon et al. 6 included six of these probands and eight additional probands ( Table 1 ). All SMCHD1 variants arose de novo from the 10 complete simplex trios, and mutations were likewise absent in unaffected family members from the remaining simplex families ( Supplementary  Fig. 1 ). Segregation of an SMCHD1 mutation was observed in all three multiplex families with available parental samples, including one (family T) in which the variant was inherited from a father who had no craniofacial abnormalities and had been contemporaneously diagnosed with muscular dystrophy. SMCHD1 is highly constrained, or intolerant to loss-of-function variation (probability of being loss-of-function intolerant (pLI) = 1.00) 11 , with an estimated prevalence of 1 in 10,000 heterozygous null individuals in ExAC. Notably, all arhinia-associated variants localized to exons 3-13 of SMCHD1 (Ensembl ENST00000320876.10), spanning a GHKL-type ATPase domain ( Table 1 and Supplementary  Table 2 ). We thus considered the possibility that this specific domain is intolerant to missense variation using models of regional constraint. We found that the entire gene is not particularly intolerant to missense variation (81% of expected missense variants observed; P = 0.016, two sided Z-test; Z-statistic = 2.14; constraint was taken from the ExAC database 10 and therefore the values to calculate 95% CI are unavailable), but this significance is driven by strong constraint in the 5′ region that harbors all detected arhinia-associated variants and encompasses the ATPase domain (exons 1-19, 61% of expected variants observed, χ 2 = 32.40, P = 1.26 × 10 −8 ; exons 20-48, 95% of expected variants observed, χ 2 = 0.86, P = 0.36; Fig. 3 ). This regional constraint suggests that these alleles may impede protein function, and in silico prediction of pathogenicity from the Combined Annotation Dependent Depletion (CADD) database revealed that the 20 arhinia-specific SMCHD1 variants were more deleterious than rare, nonsynonymous variants in ExAC (MAF < 0.01%, ExAC n = 378, P = 1.27 × 10 −5 , two-sample t-test; t = 4.42; Supplementary Fig. 2) . However, 19 missense variants in ExAC in exons 3-13 have CADD scores exceeding the median arhinia score (17.03), consistent with the observation in arhinia families that SMCHD1 variants segregated with subtle dysmorphism, no dysmorphic features and muscular dystrophy. These data support our speculation that deleterious SMCHD1 variants are not fully penetrant, and such variants alone may not be sufficient to cause arhinia.
Mutational overlap between arhinia and FSHD2
SMCHD1 is an epigenetic regulator of autosomal and X-linked genes [12] [13] [14] [15] . The discovery of an association between SMCHD1 and craniofacial development was unexpected, given that mutations in the gene are associated with FSHD2, a rare, trans-acting oligogenic form of muscular dystrophy. In FSHD2, loss of SMCHD1 repressive activity, in combination with a permissive D4Z4 haplotype at 4q35, allows for the ectopic expression of the transcript encoding the DUX4 protein, which is cytotoxic to skeletal muscle 16 . SMCHD1 mutations in FSHD2 span the entire gene and include missense and truncating variants, whereas all arhinia-associated missense variants clustered tightly around the ATPase domain (Fig. 3) , which is thought to control the release of DNA bound by SMCHD1 (ref. 17) . However, the mutational distribution was not fully distinct between these disorders; several previously reported FSHD2-specific missense variants were localized to exons 3-13, and one causal variant in FSHD2 (p.Gly137Glu) was also detected in an arhinia proband (subject AG1) 18 . Neither the FSHD2 nor the arhinia subject had features of both disorders, indicating that these phenotypes either arise by divergent mechanisms or are influenced by additional loci.
Methylation profiles in arhinia and FSHD2
Haploinsufficiency and dominant-negative loss-of-function models have been invoked for SMCHD1 mutations associated with FSHD2 (ref. 18) . In both models, loss of SMCHD1 repressive activity manifests as a decrease in DNA methylation at SMCHD1 binding sites 16, [19] [20] [21] . Although SMCHD1 interacts with numerous genetic loci, only the 4q35 D4Z4 macrosatellite array, which contains DUX4, and the highly homologous 10q26 D4Z4 array are associated with FSHD2, and hypomethylation of these two loci is assessed during diagnostic evaluation 22, 23 . To explore mechanistic overlap between arhinia and FSHD2, we quantified 4q35 D4Z4 methylation in 23 arhinia subjects (19 with SMCHD1 missense variants) and 22 family members using a bisulfite sequencing (BSS) assay specific for the FSHD2-affected D4Z4 arrays on 4q35 and 10q26 (ref. 23) . Of these family members, four harbored SMCHD1 missense variants, including two individuals with anosmia, one with a hypoplastic nose and one with muscular dystrophy (Fig. 4 and Supplementary Table 4) . We observed that 74% of arhinia subjects (and two of the four family Figure 2 Association analyses for rare mutation burden in arhinia Manhattan plot and quantile-quantile (q-q) plot demonstrating the significant accumulation of rare SMCHD1 mutations in subjects with arhinia compared to the ExAC cohort (P = 2.9 × 10 −17 , Fisher's exact test; OR = 34.4 (95 CI: 18.8-57.9)). Analyses established a variant count at each gene for arhinia subjects compared to ExAC controls (who presumably do not have arhinia; n = 60,706) after filtering for allele frequency (MAF < 0.1%), quality (mean depth ≥10; mapping quality ≥10) and predicted function (nonsynonymous, splice site and frameshift mutations). Any gene with at least one mutation passing these criteria was included in the analysis (n = 22,445 genes). Genome-wide significance threshold was P < 2.2 × 10 −6 after Bonferroni correction (red line), and only SMCHD1 exceeded this threshold.
A r t i c l e s members) with an SMCHD1 variant had D4Z4 hypomethylation characteristic of FSHD2, whereas all four arhinia subjects and 16 of the 18 family members without a missense SMCHD1 variant had normal methylation patterns. These data confirm that arhinia-specific mutations in SMCHD1 produce the same methylation patterning at D4Z4 as seen in FSHD2, demonstrating that two completely distinct phenotypes can arise from deleterious changes in the same gene and indeed the same alleles. We thus turned to animal models to probe the in vivo functional impact of SMCHD1 variants.
In vivo modeling of SMCHD1
We evaluated the functional consequences of SMCHD1 variation using zebrafish larvae. The zebrafish genome encodes one SMCHD1 ortholog (49% identical, 67% similar to human) with a highly conserved ATPase domain (Supplementary Fig. 3 ). Of relevance to BAM, eye development is highly conserved between species, making the zebrafish a robust model to study microphthalmia-associated candidate genes [24] [25] [26] . Further, D. rerio possesses two GnRH paralogs that exist in humans 27 , and GnRH neuronal ontogeny is largely conserved between humans and teleosts [28] [29] [30] . Cognizant that there is no credible zebrafish structure homologous to the human nose, we evaluated facial cartilage patterning in zebrafish as a potential surrogate phenotype in studies of smchd1 ablation or ectopic expression.
We designed and validated two morpholino antisense oligonucleotides targeting splice donor sites of two smchd1 exons encoding the ATPase domain (e3i3 and e5i5, targeting exons 3 and 5, respectively; Supplementary Fig. 3) . The e3i3 or e5i5 smchd1 morpholinos were injected (at 3, 6 or 9 ng per embryo) into −1.4col1a1:egfp embryo batches at the one-to-two-cell stage, and larvae were phenotyped quantitatively for aberrant cartilage patterning, ocular development and reproductive axis integrity 1.5-3 d after fertilization (dpf) (Fig. 5) . All morphants demonstrated dose-dependent narrowing of the ethmoid plate (Fig. 5a,b, Supplementary Fig. 4a and Supplementary Table 5 ), a dose-dependent increase in ceratohyal arch angle, delayed (or absent) development of ceratobranchial arches ( Fig. 5a and Supplementary  Fig. 4b ,c) and microphthalmia (tested at the 9-ng dose) (Fig. 5c,d and Supplementary Table 5 ). Moreover, ventral imaging of wholemount embryos immunostained with a pan-GnRH antibody revealed a prominent phenotype: morphant olfactory bulbs and hypothalami were intact, but the average projection length of the terminal nerve, where GnRH3 neurons reside, was reduced by 45% compared with controls (P = 1.35 × 10 −13 , Student's t-test, reduced by 45%, (95% CI: 39.83-50.17)) ( Table 5 ). The cartilage, eye and GnRH phenotypes were highly specific; each defect was reproduced with both morpholinos tested and rescuable with full-length human wild-type (hWT) SMCHD1 mRNA ( Fig. 5b,d,f, Supplementary Fig. 5 and Supplementary Table 5 ).
To confirm these findings, we used CRISPR/Cas9-mediated genome editing to generate small insertions and deletions into exon 1 of smchd1, achieving high mosaic fractions (Supplementary Fig. 6 ). These F0 mutants recapitulated the craniofacial, ocular and GnRH defects observed in the morphant models ( Table 5) .
Having established quantitative in vivo assays of disrupted smchd1 activity, we next tested both gain-and loss-of-function paradigms. To evaluate gain of function, we injected hWT SMCHD1 mRNA or equivalent doses of human mRNA bearing recurrent arhinia-associated variants (p.Ser135Cys, p.Leu141Phe or p.His348Arg) into zebrafish embryos; none of these overexpression assays yielded craniofacial phenotypes ( Supplementary Fig. 7a -c and Supplementary Table 5 ). Higher doses of mutant mRNA alone and combinatorial injections of mutant and hWT mRNA likewise had little effect, suggesting that, in the context of this assay, a gain-of-function biochemical mechanism is unlikely ( Supplementary Fig. 7d-f and Supplementary Table 5 ). Given that suppression of smchd1 resulted in three phenotypes relevant to BAM, we next performed in vivo complementation, focusing on our 
a Samples L1, M1, N1, P1, AF1 and AJ1 overlap with those studied in Gordon et al. 6 . b Multiplex family. c Sibling. Subjects G1, H1, H2, Q1, AD1, AI and AL1 did not show a rare missense mutation in SMCHD1. N/A, parental samples not available; M, male; F, female.
A r t i c l e s most sensitive assay, the GnRH-positive terminal nerve length. We coinjected the e5i5 morpholino with (i) full-length hWT SMCHD1 mRNA, (ii) human mRNA encoding one of three recurrent arhinia-associated variants or (iii) human mRNA encoding an FSHD2-associated missense variant (p.Pro690Ser) 16 . Full-length hWT SMCHD1 mRNA, but none of the mutant mRNAs, rescued the terminal nerve phenotype ( Fig. 5 and Supplementary Table 5 ). Complementation of mRNA with a common, presumably benign, variant from ExAC (p.Val708Ile; rs2270692) also rescued the phenotype, supporting assay specificity. The likely mode of action of the arhinia-associated alleles is therefore loss of function, and we found no foundational differences between the arhinia-specific mutations and FSHD2-associated alleles.
To extend these functional assays to a mammalian system, we introduced two variants, p.Leu141Phe and p.Glu136Asp, into mouse embryos using CRISPR/Cas9 editing. The 83 embryos recovered carried a range of variants including WT, homozygous knock-ins, homozygous knockouts, compound heterozygotes and complex deletions (Supplementary Table 6 ), but no embryos harbored heterozygous knock-in of the same allele observed in arhinia subjects. Examination of embryos at 13.5 d after conception (dpc) using optical projection tomography 31 revealed no morphological or growth anomalies (Supplementary Fig. 8 ). These results do not support a simple haploinsufficiency or a null mechanism in mammals but are consistent with previous Smchd1 knockdown studies in mice that demonstrated no craniofacial phenotype 12, 32 . These observations support the idea that mutation of a single copy of SMCHD1 alone may be insufficient to induce pathology in mammals. DUX4, the gene product responsible for FSHD, is not conserved outside of Old World monkeys and higher primates so neither the mouse nor the zebrafish genome contains orthologous sequences. The partial phenocopy associated with loss of Smchd1 in the zebrafish would therefore appear to preclude developmental overexpression of DUX4 in the olfactory placode as a mechanism of arhinia.
Protein modeling
The structure of the N-terminal region of SMCHD1, where the constrained GHKL ATPase domain resides (amino acids 111-365), is unknown. However, the crystal structure of heat shock protein 90 (Hsp90), a yeast GHKL ATPase protein, is known (PDB 2CG9), and the SMCHD1 and Hsp90 ATPase domains are structurally similar 21 . We generated a structural model of the N-terminal region of SMCHD1 with Phyre2 (ref. 33) (Fig. 6a) and found that the top ranking templates were Hsp90 structures (residues 115-573; strongest homology from residues 120-260). The structural model indicates that the arhinia-specific mutations tend to cluster on the protein surface, suggesting that these residues may be part of an interaction surface. This hypothesis is supported independently by sequence-based predictions of solvent accessibility, indicating that arhinia mutations tend to be exposed on the protein surface (Fig. 6b) .
Human expression studies and protein abundance
To initially characterize arhinia-associated SMCHD1 variants in humans, we measured SMCHD1 protein abundance and performed RNA-seq on lymphoblastoid cell lines (LCLs). We extracted protein from 23 total subjects (Supplementary Fig. 1 ) from 10 families: 10 subjects with arhinia harboring SMCHD1 variants, 11 unaffected family members without SMCHD1 mutations and 2 family members with a mutation in SMCHD1 and anosmia or a hypoplastic nose (AH3 and AH5, respectively). SMCHD1 expression was generally similar in LCLs from all subjects, as assessed by immunoblot analysis using two different anti-Smchd1 antibodies (Bethyl A302-872A-M and Abcam ab122555; Supplementary Fig. 9 ). We performed RNA-seq on a subset of 10 cases and 10 controls (unaffected family members) from the protein analysis. After confirming all mutations in the expressed transcripts, we found that arhinia subjects showed a slight but not significant decrease in SMCHD1 mRNA expression compared to controls (fold-change = 0.94, P = 0.49, permutated t-test) with no average difference in allelic expression of the missense variant compared to the reference allele (P = 0.50, paired t-test with t = 0.71, P = 0.5 (95% CI: −6.77-12.97)) (Supplementary Table 7) . These results indicate normal message stability in arhinia subjects, at least in the available LCLs. We next evaluated global patterns of differential gene expression between arhinia subjects and familial controls and, given the limited power of the data set for this rare condition, integrated these data with orthogonal ChIP and RNA-seq data from Smchd1-null mouse neural stem cells (NSCs) 13 to identify differentially expressed genes and repeat families with comparable alterations in both data sets ( Supplementary  Figs. 10 and 11 , and Supplementary Table 8) . These data revealed an enrichment of differential expression among downregulated (but not upregulated) genes in humans compared to mouse at nominal thresholds (downregulated gene enrichment P = 0.015, one-tailed Fisher's exact test; OR = 2.49; Supplementary Table 9) . From these analyses emerged a high-confidence set of nine downregulated genes that were differentially expressed in both data sets. Pathway and geneset analyses of these genes revealed that, across all 6,067 human phenotypes evaluated in ToppGene enrichment 34 , only one phenotype, 'depressed nasal tip' , achieved statistical significance (P = 6.9 × 10 −6 ; Supplementary RUs and a permissive A-type 4q sub-telomere. (c) Methylation rate determined by BSS in arhinia probands with SMCHD1 mutations for which material was available for analysis. 74% had D4Z4 hypomethylation characteristic of FSHD2, whereas the single proband tested without a SMCHD1 mutation showed a normal methylation pattern. BSS was measured from the lowest quartile as previously described 22 , and a methylation rate of <25% was considered consistent with hypomethylation observed in FSHD2. See supplementary table 4 for further details on individual methylation status.
A in SMCHD1 result in regulatory changes of genes implicated in craniofacial development, and these four genes are therefore rational mechanistic candidates for modifiers of the arhinia phenotype in the presence of SMCHD1 mutations.
Predicting comorbid FSHD2
This study identified variants in the 5′ constrained region of SMCHD1 that were associated with both FSHD2 (ref. 18 ) and arhinia. This overlap included one identical variant (p.Gly137Glu), and tested hypomethylation signatures were largely indistinguishable between arhinia and FSHD2 probands. To our knowledge, arhinia and FSHD2 have never been reported in the same individual. However, only a small subset of subjects with arhinia, an already rare condition, would be expected to harbor the requisite oligogenic architecture for FSHD2 at the D4Z4 locus, and those that do meet criteria may be too young to be symptomatic or may go undiagnosed because facial weakness might be overlooked in a patient who has undergone reconstructive craniofacial surgery. We addressed this question in subjects with available material in our cohort and identified two arhinia probands (A1 and E1) with SMCHD1 mutations who met all four clinical criteria for susceptibility to FSHD2: (i) an SMCHD1 pathogenic variant (p.Asn139His and p.Leu141Phe), (ii) D4Z4 hypomethylation (bisulfite sequencing <25%), (iii) a permissive haplotype and (iv) an 11-to 28-D4Z4 repeat unit at the 4q array 16, 22, 40, 41 (Supplementary Table 4 ). Phenotypic evaluation of A1 and E1 suggested that at least one subject had symptoms of FSHD2, suggesting yet another variant (p.Asn139His) shared by the disorders and implicating a common mechanism between disorders for these identical alleles. Five other arhinia subjects may be at risk for FSHD2 (on the basis of hypomethylation data), but material was not available for confirmatory clinical testing. Overall, these results suggest that at least two alterations (p.Gly137Glu and p.Asn139His), in the presence of a specific genetic background, can manifest as extremely divergent phenotypes.
DISCUSSION
We present genetic, genomic and functional evidence implicating SMCHD1 as the predominant driver of arhinia in humans. Overall, 84% of subjects harbored a missense mutation in a constrained region encompassing the ATPase domain of SMCHD1. Through a large collaborative effort, we were able to combine data from 24% of subjects reported in the literature with data from 21 new subjects, facilitating a uniform evaluation of the clinical phenotype associated with this condition and revealing that most subjects with arhinia who could be assessed presented with the BAM triad. These analyses represent the first evidence of a genetic cause for this rare craniofacial malformation and its associated reproductive phenotype, suggesting a novel and complex role for SMCHD1 in cranial NCC migration and/or craniofacial placode development. These observations raise broader questions about the molecular mechanisms by which mutations in the same gene can produce distinct phenotypes. For SMCHD1, these include arhinia, BAM and FSHD2. Truncation variants are common in FSHD2, but missense variants have also been reported, whereas all arhinia-associated variants were missense alleles. This suggests that the mutant SMCHD1 protein must be synthesized in arhinia and that these mutations probably interfere with one or more critical protein functions. We found largely identical hypomethylation patterns at the 4q35 D4Z4 locus in arhinia and FSHD2 probands, indicating that neither a loss nor a gain of this particular function of SMCHD1 alone (gene silencing by methylation) explains the difference in phenotype. We also investigated the possibility that arhinia-associated SMCHD1 mutations A r t i c l e s inflict genome-wide de-repression of repeat silencing but found no significant differences (Supplementary Fig. 10 ). Additional factors must therefore be involved in producing these distinct phenotypes, such as interactions with variants at other loci or disruption of SMCHD1 protein interactions that are critical to its epigenetic functions. Indeed, we found that the arhinia-specific variants tend to cluster on the surface of the protein, potentially disrupting ATP or DNA binding and/or interfering with assembly of the SMCHD1 homodimer 21 . Correspondingly, results in peripheral tissue of arhinia probands and controls precluded models of simple haploinsufficiency or overexpression resulting from these mutations, further suggesting that the bioactivity of the protein, rather than the total amount of protein, is the critical defect in humans.
Distinct findings in two model systems reinforce the complexity suggested by our data in humans. In the zebrafish model, loss of function was sufficient to drive specific phenotypes that were rescued with full-length hWT SMCHD1 mRNA but not with mRNA containing arhinia or FSHD2 variants, and overexpression conferred no discernible phenotype. In mouse, complete loss of function of Smchd1 (homozygous exon 23 nonsense mutation) produces hypomethylation, which causes female-specific embryonic lethality 12 . Heterozygosity for this nonsense mutation likewise produces no phenotype in mice, nor did CRISPR/Cas9-mediated induction of homozygous or compound heterozygous deletions in the current study. Unfortunately, we were unable to replicate the heterozygous missense genotypes characteristic of human arhinia in the mouse (Supplementary Fig. 8 ).
The fact that loss of Smchd1 produced distinctive phenotypes in zebrafish but not in mouse supports the importance of genetic background and functional interactions of the mutant protein in the pathogenesis of human arhinia.
The complex oligogenic architecture of FSHD2 suggests that only a small fraction of individuals with arhinia, an exceedingly rare condition on its own, will be at risk for FSHD2. Our analyses identified seven subjects potentially at risk for FSHD2, and at least one appears to be symptomatic. Notably, one-quarter of individuals who meet genetic criteria for FSHD2 are clinically asymptomatic, indicating that some of the factors that mediate FSHD2 are unknown 42 . The absence of arhinia in patients with FSHD2 who harbor SMCHD1 mutations within the constrained ATPase domain argues that loss of SMCHD1 activity alone is insufficient to produce a craniofacial phenotype, comparably to mutations in DNMT3B in FSHD2 patients 43, 44 . Indeed, the expressivity of this phenotype is clearly complex, as we observed family members harboring SMCHD1 mutations with only mild dysmorphism or anosmia and at least one individual without dysmorphic features. Given the epigenetic function of SMCHD1, it is plausible that one or more interacting loci influence susceptibility to arhinia. Variants at these secondary loci need not be ultra-rare: TAR syndrome (MIM274000) 45 and SMAD6-associated craniosynostosis 46 are two examples of severe developmental disorders caused by the combination of a rare, deleterious, frequently de novo mutation with a common variant. Disentangling these genetic interactions and biochemical consequences of SMCHD1 missense mutations will be a critical area of further study.
In conclusion, through an international network of collaborators we discovered that rare missense variants in an evolutionarily constrained region of SMCHD1 are the predominant cause of isolated arhinia and BAM. Using multigenerational families, we found that phenotypes associated with these mutations can be subtle or even absent in family members. The distributions of these variants and their molecular mechanisms are not fully distinct from those in FSHD2, and the molecular pathways leading from SMCHD1 dysfunction to either arhinia or FSHD2 remain unknown. Our findings thus emphasize yet another example in a growing list of genes in which mutations can give rise to pleiotropic phenotypes across the spectrum of human anomalies. For SMCHD1, these phenotypes-a rare muscle disease and a severe craniofacial and reproductive disorder-are notably diverse. Identifying the genetic modifiers influencing SMCHD1-related disease will significantly enhance understanding of the pathogenesis of the arhinia-BAM-FSHD spectra and placode biology and, more broadly, the architecture of oligogenic disorders. 
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METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. 
ONLINE METHODS
Research subject enrollment. We collected existing DNA or blood samples from 40 subjects with arhinia (23 male, 17 female). Whenever possible, DNA was also collected from family members. Phenotypic information was obtained via questionnaires completed by patients, parents or referring physicians and confirmed by review of official medical records and consultation with the referring physician. Reproductive axis dysfunction could not be determined in pre-pubertal girls or in pre-pubertal boys without congenital microphallus or cryptorchidism. All research was approved by the Institutional Review Board of Partners Healthcare. Informed consent was obtained from all subjects, of whom a subset consented to the publication of photographs (Fig. 1). WES. We performed WES on 26 total probands with arhinia (WES was performed after targeted sequencing did not detect an SMCHD1 variant for four subjects) and 11 family members. The majority of participants (n = 28) were sequenced at the Broad Institute, including 21 independent probands and 1 set of affected siblings from a consanguineous family. We also sequenced 6 unaffected family members at the Broad Institute (families A, D and E; Supplementary Fig. 1 ). We collected data for two families that had previous WES from the University of Zurich (Zurich, Switzerland; one trio (family V) and a mother-proband pair (family U)), as well as a trio (family T) with WES performed by GeneDx in which the affected proband also had a deceased great aunt with arhinia and coloboma. We also received exome results for a subject (AJ1) with arhinia from the Department of Human Genetics at Nagasaki University. WES data were aligned with BWA-MEM v.0.7.10 to GRCh37 and underwent joint variant calling by GATK 53 following best practices 54, 55 . Fig. 1 ) and performed deep WGS to 30× average coverage on an Illumina X Ten platform. Family O had multiple individuals with craniofacial abnormalities beyond the proband's arhinia, including a deceased maternal half aunt with arhinia, a sister with arhinia, a mother with anosmia and subtle nasal and dental anomalies, and a maternal grandmother with mild nasal and dental anomalies. Samples from the affected sister, unaffected brother and unaffected maternal half-aunt were obtained after WGS had been completed and were screened for the p.Gln345Arg variant by targeted sequencing. Variants were aligned with BWA-MEM v.7.7 to GRCh37, and GATK was used to call single nucleotide variants (SNVs) as described above.
WGS. We obtained samples from four members of multigenerational family O 8,9 (Supplementary
Targeted sequencing. SMCHD1 variants discovered by WES and WGS analyses were confirmed by Sanger sequencing (see Supplementary Table 11 for primers) in all subjects, except T1 and AJ1, for whom additional DNA was not available. Initial WES analyses identified rare mutations in SMCHD1 restricted to exons 3, 8-10, 12 and 13. We therefore performed targeted sequencing of these exons in subsequent subjects (n = 15). Targeted screening found rare, missense SMCHD1 variants in 10/15 subjects. Of the five SMCHD1-negative subjects, sufficient DNA was available for four to perform WES, which identified SMCHD1 variants in adjacent exons for three subjects. Of interest, targeted sequencing identified one variant (p.Leu107Pro) in individual K1 that was missed by initial WES analyses.
Association analyses.
We compared the burden of rare, nonsynonymous variants detected by WES in independent arhinia probands from an initial cohort with WES data (n = 21) from more than 60,706 controls in ExAC 10 . Analyses were restricted to include variants that passed the following criteria: (i) high quality (GATK Filter = PASS); (ii) rare (ExAC MAF < 0.1%); (iii) mean depth ≥ 10 reads; (iv) a mapping quality ≥ 10; (v) predicted to be nonsynonymous, to alter splicing, or to cause a frameshift. As there was no gender bias among our arhinia subjects to suggest sex-linkage (42.5% female), and we could not ascertain gender from the ExAC database, analyses were restricted to autosomes. Counts between ExAC and the arhinia cohort were compared by Fisher's exact test. Results were visualized as a Manhattan and QQ plot created by the R package qqman 59 .
Inheritance testing. For samples with a predicted de novo variant from targeted sequencing, we confirmed familial relationships by determining repeat length of 10 STS markers (d15s205, d12s78, d4s402, d13s170, d4s414, d22s283, d13s159, d2s337, d3s1267, d12s86). Expected parental relationships were confirmed in all families. Inheritance for proband (P1) was similarly confirmed at the University of Edinburgh with the following nine markers: cfstr1, d7s480, dxs1214, amel, nr2e3_22, d4s2366, i1cahd, d5s629, d5s823.
Transcriptome sequencing (RNA-seq). Total RNA from ~1 million cells was extracted from EBV-transformed lymphoblastoid cell lines (LCLs) using TRIzol (Invitrogen) followed by RNeasy Mini Kit (Qiagen) column purification. We prepared 20 strand-specific RNA-seq libraries (10 cases, 10 controls; Supplementary Table 7) using the Illumina TruSeq kit and the manufacturer's instructions, as described 60, 61 . Libraries were multiplexed, pooled and sequenced on multiple lanes of an Illumina HiSeq2500, generating an average of 46 million (46M) paired-end (PE) reads of 75 bp per sample, of which an average 44M PE reads passed vendor quality filters. Further quality control of sequence reads was assessed by fastQC (v.0.10.1). Subsequently, sequenced reads were N-trimmed and quality trimmed using cutadapt 62 (v.1.9.1) with options-trim-N,-quality-cutoff = 14,-minimum length = 70, which resulted in an average of 42.2M PE reads per subject. Post-trimming sequence reads were aligned to human reference genome Ensembl GRCh37 (v.71) using GSNAP 63 (19 December 2014 version) with options -N 1, -B 3,-quality-unk-mismatch = 1. Alignment quality was assessed by a custom script 60 using Picard Tools RNASeQC 64 , RSeQC 65 and SamTools 66 .
RNA-seq analyses assessed allele-specific expression for SMCHD1 variant carriers (n = 10) using Samtools mpileup (v.1.2) to call variants, requiring base and mapping quality >30. We tested for differences between allele-specific expression patterns across subjects with SMCHD1 mutations using paired t-tests. For differential expression between 10 arhinia cases and 10 unaffected familial controls, gene level counts were tabulated using BedTools's multibamcov algorithm 67 2) was applied to expression values of genes (counts per million), with the following options: alternative = two.sided, method = exact.ce, control = permControl tsmethod = abs. We compared all nominally (P < 0.05) differently expressed genes with previously published ChIP-seq and RNA-seq data of the Smchd1-null mouse 13 . A complete list of human-to-mouse homologs was retrieved from the Mouse Genome Informatics database 71 as of 9 August 2016. Enrichment of genes overlapping the RNA-seq and the ChIP-seq data was assessed with Fisher's exact test. Pathway analysis of overlapping gene lists was performed using ToppFun in the ToppGene Suite 34 , in which genes are represented by unique Ensembl IDs.
Repeat element analysis (RNA-seq). The GNSAP mapped reads from above were filtered for unique hits using the SAM flag NH:i:1. SAMtools (v0.1.19-44428cd) 'sort' was used to sort reads by coordinate and subsequently to remove potential PCR duplicates using 'rmdup' . The human (hg19) repeatmasker annotation was downloaded from the UCSC Genome Browser using 'Table browser' and reshaped using custom R scripts (v3.1.0) to the format chr/start/stop/strand/Repeat_name/Repeat_class/Repeat_family/unique_ identifier. BEDTools (v2.23.0) interesectBED was used to inner join mapped reads against the hg19 repeatmasker modified table in Unix. Next, the R 'table' function was implemented to count the frequency of unique ID repeat elements within the intersectBed outputs. Counts from controls and patients were concatenated into a master table and analyzed using the R packages edgeR 72 (v3.8.6 ) and DESeq2 (ref. 73) (v1.18.0). Finally, beeswarm (v0.2.3) was used to plot control and patient median repeat levels across annotated LTR, L1, L2, Satellite and SINE repeats using Student's t-test to test for significant differences between groups.
Immunoblotting. Protein was harvested from 1M LCLs in 23 total subjects: 10 subjects with arhinia and harboring SMCHD1 mutations, 11 unaffected family members without SMCHD1 mutations and two family members with a mutation in SMCHD1 and anosmia or a hypoplastic nose (AH3 and AH5, respectively; Supplementary Fig. 9 ). Protein extraction was performed with the following procedure. Cells were washed in 1× PBS and lysed in 300 µl ice-cold 1× RIPA buffer (bioWorld) supplemented with 5 mM PMSF. After 30 min incubation on ice, cell lysates were cleared by centrifugation (15 × g, 15 min, 4 °C) and soluble protein concentration was assayed with a Pierce BCA protein assay kit. Extracted proteins (15-30 µl/sample) were next separated by 8% SDS-PAGE (Bio-Rad MiniProtean 3 Cell, 2 h 15 mA) and transferred onto a polyvinylidene fluoride (PVDF) membrane (Bio-Rad) using liquid transfer system (Bio-Rad Ready Gel Cell) at 4 °C, 10 V for 16 h. Immunoblotting was performed using two sets of antibodies to SMCHD1: Bethyl Laboratories A302-872A-M (anti-SMCHD1, C terminus) and Abcam ab122555 (anti-SMCHD1, N terminus). We used two loading control antibodies: Abcam ab6046 (β-tubulin loading control) and Abcam ab8227 (β-actin loading control). Antibody dilutions were used as recommended by manufacturer. Primary antibodies were diluted in TBS and Tween 20 (TBST) buffer and 1% BSA, secondary HRP-conjugated antibody (1:20,000 dilution) in TBST without BSA. The membrane was cut alongside 75 kDa marker (Bio-Rad Precision Plus Protein standards), and the upper part was used for SMCHD1 (molecular weight (MW) = 250 kDa), and the lower part for β-tubulin (MW = 50 kDa) and β-actin (MW = 42 kDa) controls. Blotting with primary antibody was carried out overnight at 4 °C on a rocking platform, followed by three 10-min washes in TBST at room temperature. Blotting with secondary antibody was carried out at room temperature for 1 h, followed by three 10-min washes in TBST. When re-blotting SMCHD1 with an alternative antibody, the previously used primary antibody was stripped off with mild stripping buffer, as recommended in Abcam's stripping-for-reprobing protocol. Blots were luminesced with ECL reagent (Bio-Rad) and developed with the ChemiDoc MP system (Bio-Rad). Automated protein quantification was done using Image Lab 5.2.1 software (Bio-Rad).
CRISPR/Cas9 genome editing in mouse embryos. To generate mouse embryos carrying the p.Leu141Phe disease-associated missense variant in Smchd1, a double-stranded DNA oligomer that provides a template for the guide RNA sequence was cloned into px461 (see Supplementary Table 11 ). The full gRNA template sequence was amplified from the resulting px461 clone using universal reverse primer and T7 tagged forward primers. The guide RNA PCR template was used for in vitro RNA synthesis with T7 RNA polymerase (New England Biolabs), and the RNA template was subsequently purified using an RNeasy mini kit (Qiagen) purification columns. Cas9 mRNA was procured from Tebu Bioscience. The wild-type and mutant repair templates for Phe141/Leu141 (chr17:71,463,705-71,463,818 GRCm38) and Glu136/Asp136 (chr17:71,463,701-71,463,822 GRCm38) were synthesized as 114-bp ultramers bearing the desired sequence change from IDT. The injection mix contained Cas9 mRNA (50 ng/µl), guide RNA (25 ng/µl) and repair template DNA (150 ng/µl). Injections were performed in mouse zygotes, and the embryos were later harvested for analysis at 11.5 and 13.5 dpc.
Optical projection tomography. Whole mouse embryos were mounted in 1% agarose, dehydrated in methanol and then cleared overnight in BABB (1:2 benzyl alcohol:benzyl benzoate). The sample was then imaged using a Bioptonics OPT Scanner 3001 (Bioptonics) using tissue autofluorescence (excitation 425 nm, emission 475 nm) to capture the anatomy. The resulting images were reconstructed using Bioptonics proprietary software, automatically thresholded and merged to a single 3D image output using Bioptonics Viewer software.
DNA methylation analysis. The DNA methylation status of the D4Z4 region was assayed as described 22 . Bisulfite conversion was performed on 1 µg genomic DNA using the EpiTect Bisulfite Kit (Qiagen) per the manufacturer's instructions, and 200 ng of converted genomic DNA was used for PCR. Bisulfite sequencing (BSS) analysis of 52 CpGs in the DUX4 promoter region of the 4q and 10q D4Z4 repeats was performed using primers BSS167F and BSS1036R followed by nested PCR with BSS475F and BSS1036R using 10% of the first PCR product (primer sequences are listed in Supplementary Table 11) . PCR products were cloned into the pGEM-T Easy vector (Promega), sequenced, and analyzed using web-based analysis software BISMA (http:// biochem.jacobs-university.de/BDPC/BISMA/) 74 with the default parameters. Standard genomic PCR was performed on nonconverted DNA to identify the 4qA, 4qA-L and 4qB chromosome 75 . Specific 4q and 10q haplotypes were identified and assigned as previously described 76, 77 . The presence of the DUX4 polyadenylation site was determined by BS-PCR as previously described 42 .
Determination of 4q35 and 10q26 D4Z4 array sizes. Peripheral blood leukocytes or cultured lymphoblasts were embedded in agarose plugs and digested with three different restriction enzymes (EcoRI, EcoRI/BlnI and XapI). Restriction fragments were separated by pulsed-field gel electrophoresis (PFGE) and visualized by Southern blot with a p13E-11 probe. For some subjects, the Southern blot were rehybridized with a D4Z4 probe 78 .
Gene suppression and in vivo complementation in zebrafish embryos. Splice-blocking morpholinos (MOs) targeting the Danio rerio smchd1 exon 3 splice donor (e3i3) or exon 5 splice donor (e5i5) were designed and synthesized by Gene Tools LLC (Supplementary Table 11) . To determine the optimal MO dose for in vivo complementation studies, we injected increasing doses (3 ng, 6 ng, and 9 ng of each MO; 1 nl MO injected per embryo; 1-to 2-cell stage) into -1.4col1a1:egfp 79 embryos harvested from natural mating of heterozygous transgenic adults maintained on an AB background. To determine MO efficiency, we used TRIzol (Thermo Fisher) to extract total RNA from embryos at 1 dpf according to the manufacturer's instructions. Resulting total RNA was reverse transcribed into cDNA using the Superscript III Reverse Transcriptase kit (Thermo Fisher) and used as template in RT-PCR reactions to amplify regions flanking MO target sites. RT-PCR products were gel purified using the QIAquick gel extraction kit (Qiagen), cloned (TOPO-TA; Invitrogen), and plasmid purified from individual colonies was Sanger sequenced according to standard protocols to identify the precise alteration of endogenous transcript. For rescue experiments, a wild-type (WT) human SMCHD1 ORF (GenBank NM_015295) construct was obtained commercially (OriGene Technologies) and subcloned into the pCS2+ vector. Point mutations were introduced into pCS2+ vectors as described 80 , and all vectors were sequence confirmed. WT and variant SMCHD1 constructs were linearized with NotI, and mRNA was transcribed using the mMessage mMachine SP6 transcription kit (Thermo Fisher). Unless otherwise noted, 9 ng MO (either e3i3 or e5i5) was used in parallel or in combination with 25 pg SMCHD1 mRNA for in vivo complementation studies.
CRISPR/Cas9 genome editing in zebrafish embryos. We used CHOPCHOP 81 to identify a guide (g)RNA targeting a sequence within the smchd1 coding regions (see Supplementary Table 11 ). gRNAs were in vitro transcribed using the GeneArt precision gRNA synthesis kit (Thermo Fisher) according to the manufacturer's instructions. Zebrafish embryos were obtained from -1.4col1a1: egfp embryos harvested from natural mating of heterozygous transgenic adults maintained on an AB background; 1 nl of injection cocktail containing 100 pg/nl gRNA and 200 pg/nl Cas9 protein (PNA Bio) was injected into the cell of embryos at the 1-cell stage. To determine targeting efficiency in founder (F0) mutants, we extracted genomic DNA from 2 dpf embryos and PCR amplified the region flanking the gRNA target site. PCR products were denatured, reannealed slowly and separated on a 15% TBE 1.0-mm precast polyacrylamide gel, which was then incubated in ethidium bromide and imaged on a ChemiDoc system (Bio-Rad) to visualize hetero-and homoduplexes. To estimate the percentage of mosaicism of smchd1 F0 mutants (n = 5), PCR products were gel purified (Qiagen), and cloned into a TOPO-TA vector (Thermo Fisher). Plasmid was prepped from individual colonies (n = 10-12 colonies/embryo) and Sanger sequenced according to standard procedures.
Phenotypic analyses in zebrafish.
To study craniofacial structures (cartilage or eye development), larval batches were reared at 28 °C and imaged live at 3 dpf using the Vertebrate Automated Screening Technology Bioimager (VAST; software version 1.2.2.8; Union Biometrica) mounted on an AxioScope A1 (Zeiss) microscope using an Axiocam 503 monochromatic camera and Zen Pro 2012 software (Zeiss). Fluorescence imaging of GFP-positive cells on ventrally positioned larvae was conducted as described 82 . In parallel, we obtained lateral brightfield images of whole larvae using the VAST onboard camera.
To evaluate gonadotropin-releasing hormone (GnRH) neurons, 1.5 dpf embryos were dechorionated and fixed in a solution of 4% PFA and 7% picric acid for 2 h at room temperature. Embryos were then washed with a solution of PBS with 0.1% Triton X-100 (PBS-T) and stored at 4 °C until staining. For whole-mount immunostaining, embryos were washed briefly with 0.1% trypsin in PBS, washed in PBS-T and dehydrated at -20 °C in pre-chilled 100% acetone for 15 min. Next, embryos were washed in PBS-T and blocked in a solution of 2% BSA, 1% DMSO, 0.5% Triton X-100 and 5% calf serum for 1 h at room temperature. We used rabbit anti-GnRH antibody (1:500 dilution; SigmaAldrich, G8294) for primary detection. After overnight incubation of primary antibody, embryos were washed with blocking solution and incubated with Alexa Fluor 555 anti-rabbit secondary antibody (1:500; Thermo Fisher) for 2 h at room temperature. Images were acquired manually with an AxioZoom. V16 microscope and Axiocam 503 monochromatic camera and were z-stacked using Zen Pro 2012 software (Zeiss). Cartilage structure, eye area, and GnRH neuron projection length was measured using ImageJ (NIH); pairwise comparisons to determine statistical significance were calculated using Student's t-test. For ceratobranchial pair counts, we used a χ 2 test to determine statistical significance. All experiments were repeated at least twice.
Statistics and general methods. For zebrafish studies, sample size was based on prior experiments to evaluate similar phenotypes 25, 82 . For mouse studies, given that we were looking for a dichotomous effect, we set up the CRISPR experiment with both wild-type and mutant repair template, which is our standard practice for modeling heterozygous variants. The gRNA was very efficient in targeting the locus, so >50 embryos was chosen as a reasonable number. For mouse studies, we scored the phenotype visually prior to genotyping. For zebrafish studies, injections and scoring were accomplished with the investigator blinded to the experimental condition. The phenotype was scored on mouse embryo dissection prior to genotyping. None of the embryos was thought to be craniofacially abnormal. After genotyping, we chose the genotypes to compare and performed optical projection tomography (OPT), which showed no difference.
Data availability. Sequencing data are available under dbGaP accession phs001246.v1.p1. SMCHD1 variant information has been deposited at ClinVar under accessions SCV000328594-SCV000328618.
